Top-Rated StocksTop-RatedNASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis $10.01 -0.45 (-4.30%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$9.68▼$10.5850-Day Range$7.28▼$11.9052-Week Range$3.21▼$18.33Volume6.73 million shsAverage Volume7.61 million shsMarket Capitalization$2.80 billionP/E RatioN/ADividend YieldN/APrice Target$24.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Iovance Biotherapeutics alerts: Email Address Iovance Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside139.8% Upside$24.00 Price TargetShort InterestBearish24.47% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.28Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.26) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.86 out of 5 starsMedical Sector188th out of 910 stocksBiological Products, Except Diagnostic Industry23rd out of 155 stocks 3.5 Analyst's Opinion Consensus RatingIovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIovance Biotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Iovance Biotherapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted24.47% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Iovance Biotherapeutics has recently decreased by 3.25%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIovance Biotherapeutics has received a 42.33% net impact score from Upright. Iovance Biotherapeutics seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Iovance Biotherapeutics is -0.82. Previous Next 2.4 News and Social Media Coverage News SentimentIovance Biotherapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Iovance Biotherapeutics this week, compared to 6 articles on an average week.Search Interest52 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 108% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -72% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iovance Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.26) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Iovance Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Iovance Biotherapeutics Stock (NASDAQ:IOVA)Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Read More IOVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOVA Stock News HeadlinesSeptember 6 at 9:30 AM | fool.comThis Is the Biggest Risk With Iovance Biotherapeutics StockSeptember 3, 2024 | benzinga.com(IOVA) - Analyzing Iovance Biotherapeutics's Short InterestSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. September 3, 2024 | globenewswire.comIovance Biotherapeutics to Present at Upcoming ConferencesSeptember 2, 2024 | fool.com3 Monster Biotech Stocks to Buy Before 2025September 2, 2024 | finance.yahoo.comPipeline Moves: Investigator-led oncology cell therapy trial terminatedSeptember 2, 2024 | americanbankingnews.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $24.00 Average Target Price from AnalystsAugust 30, 2024 | nasdaq.comOctober 11th Options Now Available For Iovance Biotherapeutics (IOVA)September 7, 2024 | True Gold Republic (Ad)China Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . August 30, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Repare Therapeutics (RPTX)August 27, 2024 | fool.comUp 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?August 18, 2024 | uk.finance.yahoo.comIOVA Aug 2024 7.000 putAugust 16, 2024 | uk.investing.comIovance Biotherapeutics stock retains buy rating on strong revenue outlookAugust 16, 2024 | globenewswire.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)August 14, 2024 | nz.finance.yahoo.comIovance Biotherapeutics Inc (2LB.DU)August 14, 2024 | finance.yahoo.comIndustry Analysts Just Made A Sizeable Upgrade To Their Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Revenue ForecastsAugust 12, 2024 | markets.businessinsider.comIovance Biotherapeutics Poised for Strong Market Position and Financial Growth: Buy Rating AffirmedAugust 11, 2024 | seekingalpha.comIovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)See More Headlines Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IOVA CUSIPN/A CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees500Year Founded2013Price Target and Rating Average Stock Price Target$24.00 High Stock Price Target$34.00 Low Stock Price Target$10.00 Potential Upside/Downside+139.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-444,040,000.00 Net Margins-1,343.27% Pretax Margin-1,361.17% Return on Equity-65.04% Return on Assets-50.79% Debt Debt-to-Equity RatioN/A Current Ratio5.15 Quick Ratio4.85 Sales & Book Value Annual Sales$32.77 million Price / Sales85.47 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book3.64Miscellaneous Outstanding Shares279,833,000Free Float250,730,000Market Cap$2.80 billion OptionableOptionable Beta0.63 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Frederick G. Vogt Esq. (Age 50)J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary Comp: $1.39MMr. Jean-Marc Bellemin M.B.A. (Age 51)CFO, Principal Accounting Officer & Treasurer Comp: $932.2kDr. Igor P. Bilinsky (Age 51)Chief Operating Officer Comp: $932.2kDr. Friedrich Graf Finckenstein M.D. (Age 57)Chief Medical Officer Comp: $1.06MMs. Sara PellegrinoVice President of Investor Relations & Public RelationsMs. Tracy WintonSenior Vice President of Human ResourcesMr. Howard B. Johnson M.B.A. (Age 64)Chief Business Officer Mr. James Ziegler M.B.A.Executive Vice President of CommercialDr. Raj K. Puri M.D.Ph.D., Executive VP of Regulatory Strategy & Translational MedicineMr. Brian Shew M.B.A.Senior VP & Head of Digital and Information TechnologyMore ExecutivesKey CompetitorsTwist BioscienceNASDAQ:TWSTChina Biologic ProductsNASDAQ:CBPORelay TherapeuticsNASDAQ:RLAYFate TherapeuticsNASDAQ:FATENektar TherapeuticsNASDAQ:NKTRView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Bought 13,296 shares on 8/19/2024Ownership: 0.005%Susquehanna International Group LLPBought 219,900 shares on 8/16/2024Ownership: 0.000%Creative PlanningSold 5,470 shares on 8/16/2024Ownership: 0.026%Algert Global LLCSold 3,492 shares on 8/16/2024Ownership: 0.013%Cim Investment Management Inc.Bought 17,399 shares on 8/16/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions IOVA Stock Analysis - Frequently Asked Questions How have IOVA shares performed this year? Iovance Biotherapeutics' stock was trading at $8.13 on January 1st, 2024. Since then, IOVA stock has increased by 23.1% and is now trading at $10.01. View the best growth stocks for 2024 here. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) released its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. The business's quarterly revenue was up 12969.7% on a year-over-year basis. Who are Iovance Biotherapeutics' major shareholders? Iovance Biotherapeutics' top institutional investors include Perceptive Advisors LLC (9.27%), Long Focus Capital Management LLC (1.48%), Hood River Capital Management LLC (0.98%) and Principal Financial Group Inc. (0.91%). Insiders that own company stock include Wayne P Rothbaum, Merrill A Mcpeak, Iain D Dukes and Frederick G Vogt. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN) and Xtrackers California Municipal Bond ETF (CA). This page (NASDAQ:IOVA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.